Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years [ID6537]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 26 August 2026
Botulinum toxin injection to cricopharyngeal muscle for retrograde cricopharyngeal dysfunction (RCPD)Status:Topic prioritisationProgramme:Interventional procedures guidanceExpected publication date: TBC
Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitisStatus:In developmentProgramme:Interventional procedures guidanceExpected publication date: TBC
DB-OTO for Hearing loss [ID6728]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal) (TA1123)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 January 2026
Digital tools and platforms to support the early detection and initial diagnosis of hearing lossStatus:Awaiting developmentProgramme:Health technology evaluationExpected publication date: TBC
Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (review of TA648) [ID6480]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 18 February 2026
Hearing aids for adults with hearing lossStatus:In developmentProgramme:Health technology evaluationExpected publication date: 27 January 2027
Mercaptamine hydrochloride for treating corneal cystine crystal deposits in people 6 months to under 2 years with cystinosis [TSID12261]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 9 September 2026